Palbociclib
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 μmol/L) and Cdk6 (IC50, 0.016 μmol/L), having no activity against a panel of 36 additional protein kinases.
中文名 帕博西林，帕博昔布 外文名Palbociclib 原研企業 美國輝瑞制藥（Pfizer） 藥物類別 吡啶并嘧啶衍生化的CDK抑制劑
Palbociclib的生物活性
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 μmol/L) and Cdk6 (IC50, 0.016 μmol/L), having no activity against a panel of 36 additional protein kinases.
化學信息:
外觀：黃色至灰白色晶狀固體
分子量: 447.53
分子式: C24H29N7O2
CAS號: 571190-30-2
溶劑/溶解度: DMSO
晶型：2種，A和B，均為無水晶體
儲存條件: 參考CoA中推薦的條件進行儲存。 |
